doi:10.1186/1477-7827-9-67 Zhang M, Niu W, Wang Y, et al
There's truth
Recognizing Lean Liver Disease in Clinical Practice Clinicians should consider metabolic liver disease in patients who present with: Normal BMI but central adiposity (increased waist circumference) Mildly elevated liver enzymes without a clear cause Dyslipidemia or insulin resistance features Fatty liver on incidental imaging Routine use of noninvasive tests such as FIB4, ELF score, or transient elastography can help stratify risk and guide hepatology referrals
Additionally, there have been rare reports of non-arteritic anterior ischaemic optic neuropathy (NAION) in observational studies of semaglutide, though a causal relationship has not been established and regulatory authorities continue to monitor this signal
Clinical data show moderate improvement in pigment index, not dramatic shade changes
Traditionally, orally administered vitamins and drugs have low bioavailability, meaning that the product loses potency while it is being metabolized, before it is absorbed by the cells in the body Liposomal delivery takes this a step further by mimicking the structure of a cell membrane
